Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

This study is comparing two treatment strategies for people with operable head and neck squamous cell cancer (stage III or IVA): receiving chemotherapy and an immunotherapy drug (tislelizumab) before surgery versus going straight to surgery. Researchers want to find out if giving immune-boosting treatment first leads to better outcomes. **You may be eligible if:** - You have been diagnosed with head and neck squamous cell cancer (stage III or IVA) and surgery is planned - You are between 18 and 79 years old - Your physical fitness score (ECOG) is 0 or 1 - Your cancer shows measurable disease on scans - You have not previously received immunotherapy drugs - Your liver, kidney, and blood counts are within acceptable ranges **You may NOT be eligible if:** - You have received prior immunotherapy (such as anti-PD-1 or anti-CTLA-4 drugs) - You have already had treatment for this cancer - Your organ function is too poor to tolerate treatment - Your cancer has spread to distant sites Talk to your doctor to see if this trial is right for you.